Scientists test First-of-its-Kind HIV vaccine in early human trial
NCT ID NCT06033209
Summary
This is an early-stage study to check the safety and immune response of a new experimental HIV vaccine in healthy adults who do not have HIV. Researchers will give the vaccine candidate, which uses a protein from the HIV virus combined with an immune-boosting particle, to 57 volunteers. The main goal is to find a safe dose and see if it triggers the desired type of immune response, which is a first step in a long process toward a potential vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta - Hope Clinic
Decatur, Georgia, 30030, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham & Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Medical Center
New York, New York, 100032, United States
-
New York Blood Center
New York, New York, 10065, United States
-
Penn Prevention CRS [Site ID: 30310]
Philadelphia, Pennsylvania, 19104, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Vanderbilt Institute for Infection, Immunology and Inflammation
Nashville, Tennessee, 37232-2582, United States
Conditions
Explore the condition pages connected to this study.